$NTLA
Intellia Therapeutics, Inc.

2017 Q1 Form 10-K Financial Statement

#000119312517082186 Filed on March 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q3
Revenue $6.215M $5.630M $4.870M
YoY Change 249.16% 233.14% 188.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.730M $5.120M $4.710M
YoY Change 76.31% 82.21% 207.84%
% of Gross Profit
Research & Development $13.43M $11.33M $7.861M
YoY Change 157.05% 158.99% 127.33%
% of Gross Profit
Depreciation & Amortization $660.0K $400.0K $270.0K
YoY Change 252.94% 207.69% 170.0%
% of Gross Profit
Operating Expenses $13.43M $11.33M $7.861M
YoY Change 157.05% 158.99% 127.33%
Operating Profit -$12.95M -$10.82M -$7.697M
YoY Change 93.43% 97.09% 133.17%
Interest Expense $320.0K $260.0K $220.0K
YoY Change 3100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.63M -$10.56M -$7.482M
YoY Change 88.82% 92.37% 126.66%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.63M -$10.56M -$7.482M
YoY Change 88.83% 101.39% 147.83%
Net Earnings / Revenue -203.23% -187.62% -153.63%
Basic Earnings Per Share
Diluted Earnings Per Share -$363.8K -$305.3K -$217.9K
COMMON SHARES
Basic Shares Outstanding 36.02M shares 36.00M shares 36.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $257.6M $273.1M $290.6M
YoY Change 301.25% 260.29% 251.82%
Cash & Equivalents $257.6M $273.1M $290.6M
Short-Term Investments
Other Short-Term Assets $1.100M $1.800M $1.000M
YoY Change 57.14% 125.0% 66.67%
Inventory
Prepaid Expenses
Receivables $2.443M $6.454M $1.112M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $261.1M $281.3M $292.7M
YoY Change 295.95% 262.39% 247.21%
LONG-TERM ASSETS
Property, Plant & Equipment $11.42M $10.63M $5.492M
YoY Change 170.06% 292.47% 174.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.767M $7.035M $3.275M
YoY Change 25.9% 289.75% 118.33%
Total Long-Term Assets $18.19M $17.66M $8.767M
YoY Change 89.37% 291.38% 157.85%
TOTAL ASSETS
Total Short-Term Assets $261.1M $281.3M $292.7M
Total Long-Term Assets $18.19M $17.66M $8.767M
Total Assets $279.3M $299.0M $301.5M
YoY Change 269.69% 263.98% 243.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.434M $4.652M $657.0K
YoY Change 18.91% 242.06% -6.14%
Accrued Expenses $3.559M $5.900M $4.810M
YoY Change 19.71% 111.62% 45.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.91M $30.73M $22.63M
YoY Change 127.28% 187.33% 117.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $378.0K $293.0K $306.0K
YoY Change 8.31% -9.29% -94.0%
Total Long-Term Liabilities $378.0K $293.0K $306.0K
YoY Change 8.31% -9.29% -94.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.91M $30.73M $22.63M
Total Long-Term Liabilities $378.0K $293.0K $306.0K
Total Liabilities $25.29M $31.02M $22.94M
YoY Change 123.61% 181.57% 48.95%
SHAREHOLDERS EQUITY
Retained Earnings -$66.20M -$53.57M -$43.01M
YoY Change 131.27% 144.21%
Common Stock $266.1M $263.4M $261.1M
YoY Change 17842.28% 35737.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $199.9M $209.8M $218.1M
YoY Change
Total Liabilities & Shareholders Equity $279.3M $299.0M $301.5M
YoY Change 269.69% 263.98% 243.75%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$12.63M -$10.56M -$7.482M
YoY Change 88.83% 101.39% 147.83%
Depreciation, Depletion And Amortization $660.0K $400.0K $270.0K
YoY Change 252.94% 207.69% 170.0%
Cash From Operating Activities -$11.40M -$14.41M -$7.610M
YoY Change 21.02% 162.48% 132.72%
INVESTING ACTIVITIES
Capital Expenditures $4.162M -$3.410M -$600.0K
YoY Change 312.9% 305.95% -1.64%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$4.160M -$3.410M -$600.0K
YoY Change 311.88% 305.95% 5900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K 260.0K -1.860M
YoY Change -104.17% -157.78% -102.81%
NET CHANGE
Cash From Operating Activities -11.40M -14.41M -7.610M
Cash From Investing Activities -4.160M -3.410M -600.0K
Cash From Financing Activities 50.00K 260.0K -1.860M
Net Change In Cash -15.51M -17.56M -10.07M
YoY Change 33.36% 159.0% -116.03%
FREE CASH FLOW
Cash From Operating Activities -$11.40M -$14.41M -$7.610M
Capital Expenditures $4.162M -$3.410M -$600.0K
Free Cash Flow -$15.56M -$11.00M -$7.010M
YoY Change 49.23% 136.56% 163.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
30000000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
30000000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
331000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
0
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36022502 shares
CY2016Q2 dei Entity Public Float
EntityPublicFloat
453203965
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9845000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
7566000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1281000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2558755 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2558755 shares
CY2015Q4 us-gaap Assets
Assets
82139000
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
811000
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q4 us-gaap Assets Current
AssetsCurrent
77626000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7452000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
211000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
735000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
418000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75816000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3765000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1360000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6547000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
811000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
907000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8263000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4653000
CY2015Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
811000
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2151000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2788000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82139000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
323000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10695000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1805000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2708000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3039000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-21201000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.04
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2227276 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.81
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
88557000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21936000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
810000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
456374 shares
CY2015Q4 ntla Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
830000
CY2015Q4 ntla Remaining Obligation Acquired In Process Research And Development
RemainingObligationAcquiredInProcessResearchAndDevelopment
600000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2703000
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
270448000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Deferred Tax Liabilities Deferred Expense Reserves And Accruals
DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
1028000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
270448000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1193000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
31500000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1430000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1940000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36018540 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36018540 shares
CY2016Q4 us-gaap Assets
Assets
298969000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1028000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q4 us-gaap Assets Current
AssetsCurrent
281306000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20549000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2016Q4 us-gaap Contractual Obligation
ContractualObligation
0
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
3200000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
263403000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1873000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
273064000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6454000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
58109000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4652000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20178000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1028000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3197000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
35800000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21577000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13751000
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2035000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5900000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
298969000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
293000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30730000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7035000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14482000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10628000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12058000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.03
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
209837000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13500000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.35
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
142964 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1361855 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.81
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53570000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1788000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1012000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3040214 shares
CY2016Q4 ntla Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
785000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13536000 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
308000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9845000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.55
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.045 pure
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.380 pure
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.006 pure
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
36000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2379000
us-gaap Depreciation
Depreciation
3000
us-gaap Costs And Expenses
CostsAndExpenses
9539000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23764000 shares
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
685000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
65971000
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-51.02
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.044 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.360 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.018 pure
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
219000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8283000
CY2015 us-gaap Depreciation
Depreciation
328000
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
19453000
us-gaap Proceeds From Issuance Of Common Limited Partners Units
ProceedsFromIssuanceOfCommonLimitedPartnersUnits
349000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1056000
us-gaap Net Income Loss
NetIncomeLoss
-9539000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
12651000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9539000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-575000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
163000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
285000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
256000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9539000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
173000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12742000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2322000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
275000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
6055000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
349000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1105000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation
ShareBasedCompensation
308000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
826000 shares
ntla Stock Issued During Period Value New Issues Preferred
StockIssuedDuringPeriodValueNewIssuesPreferred
12393000
ntla Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.011 pure
ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
258000
ntla Earnings Per Common Unit Basic And Diluted
EarningsPerCommonUnitBasicAndDiluted
-11.55
ntla Weighted Average Number Of Common Units Outstanding Basic And Diluted
WeightedAverageNumberOfCommonUnitsOutstandingBasicAndDiluted
826000 shares
ntla In Process Research And Development Acquired But Not Yet Paid
InProcessResearchAndDevelopmentAcquiredButNotYetPaid
1700000
ntla Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
300000
ntla Noncash Portion Of Acquired In Process Research And Development
NoncashPortionOfAcquiredInProcessResearchAndDevelopment
4055000
CY2014 ntla Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
3600000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.076 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2015 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
1100000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
805000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-12397000
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
74661000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13409000
CY2015 ntla Effect Of Reorganization
EffectOfReorganization
-20671000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2554000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
6044000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
335000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
525000
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
76000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-13409000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
150000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
70288000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
CY2015 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-1012000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9312000
CY2015 us-gaap Income Tax Effects Allocated Directly To Equity
IncomeTaxEffectsAllocatedDirectlyToEquity
1000000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1012000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1763000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2554000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1984000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11170000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.826 pure
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
602000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.24
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015 pure
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1308000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
243000 shares
CY2015 ntla Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.033 pure
CY2015 ntla Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
3800000
CY2015 ntla Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
970000
CY2015 ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
2671000
CY2015 ntla Collaboration Consideration Allocated To Equity
CollaborationConsiderationAllocatedToEquity
2600000
CY2015 ntla In Process Research And Development Acquired But Not Yet Paid
InProcessResearchAndDevelopmentAcquiredButNotYetPaid
600000
CY2015 ntla Effective Income Tax Rate Reconciliation Intraperiod Tax Allocation
EffectiveIncomeTaxRateReconciliationIntraperiodTaxAllocation
-0.067 pure
CY2016 dei Entity Registrant Name
EntityRegistrantName
INTELLIA THERAPEUTICS, INC.
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4402000 shares
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001652130
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6715000
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
197248000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.42
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.067 pure
CY2016 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
88557000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.416 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.028 pure
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3090000
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16798000
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 10pt"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 10pt"> The Company&#x2019;s cash and cash equivalents may potentially be subject to concentrations of credit risk. The Company generally maintains balances in various operating accounts in excess of federally insured limits with financial institutions that management believes to be of high credit quality.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 10pt"> Accounts receivable represent amounts due from collaboration partners. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. As of December&#xA0;31, 2016, the Company&#x2019;s two collaboration partners, Regeneron Pharmaceuticals, Inc. (&#x201C;Regeneron&#x201D;) and Novartis Institutes for BioMedical Research, Inc. (&#x201C;Novartis&#x201D;), accounted for all of the Company&#x2019;s accounts receivable. As of December&#xA0;31, 2015, Novartis accounted for all of the Company&#x2019;s accounts receivable.</p> </div>
CY2016 us-gaap Depreciation
Depreciation
1104000
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
48638000
CY2016 dei Trading Symbol
TradingSymbol
NTLA
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31840000
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1284000 shares
CY2016 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
600000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3050000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-31634000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31634000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6165000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5454000
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
16479000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1784000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
979000
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6435000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-32159000
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-30000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
167304000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-13000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
67975000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
525000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
36109000
CY2016 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6165000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
170507000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.34
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
257 shares
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 10pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 10pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The preparation of the Company&#x2019;s consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#x201C;U.S.&#x201D;) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the valuation of common and incentive units for the periods prior to the Company&#x2019;s stock becoming publicly traded. Estimates are periodically reviewed in light of changes in circumstances, facts and experiences. Actual results may differ materially from management&#x2019;s estimates, judgments and assumptions.</p> </div>
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1110000
CY2015Q1 us-gaap Costs And Expenses
CostsAndExpenses
2481000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-1093000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1195000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.83
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
864230 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1191 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.34
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.81
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.81
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
167139000
CY2016 us-gaap Temporary Equity Accretion Of Interest
TemporaryEquityAccretionOfInterest
0
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.880 pure
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2764000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2614707 shares
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
259000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.48
CY2015Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1286000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1195000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-102000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1371000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
30610 shares
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
6715000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22222000 shares
CY2016 ntla Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.019 pure
CY2016 ntla Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
13100000
CY2016 ntla Deferred Tax Assets Operating Loss Carryforwards Expiration Year
DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear
2034
CY2016 ntla Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
-88557000
CY2016 ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
100000
CY2016 ntla Deferred Tax Assets Operating Loss Carryforwards Expiration Description
DeferredTaxAssetsOperatingLossCarryforwardsExpirationDescription
Begin to expire in 2034
CY2016 ntla Deferred Tax Assets Tax Credit Carryforwards Research Expiration Description
DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationDescription
Begin to expire in 2034 and 2029
CY2016 ntla Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
259000
CY2016 ntla Percentage Likelihood Of Realization Required To Record Tax Benefit
PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit
0.500 pure
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.37
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2833000
CY2015Q2 us-gaap Costs And Expenses
CostsAndExpenses
4799000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3040000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3422000
CY2015Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1377000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3422000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-382000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1966000
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1284000 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.89
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3246000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
8471000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-6689000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6689000
CY2016Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1777000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6694000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5225000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
676000 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3729000
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
11152000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6900000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6900000
CY2016Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
4206000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6946000
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
46000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7423000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19121000 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.27
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1531000
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
4989000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-3019000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3301000
CY2015Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1688000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3301000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-282000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3458000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
294000 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4705000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
12566000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-7482000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7482000
CY2016Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
4869000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7697000
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
215000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7861000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34316000 shares
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.57
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2809000
CY2015Q4 us-gaap Costs And Expenses
CostsAndExpenses
7184000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-5245000
CY2015Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5491000
CY2015Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1693000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5491000
CY2015Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-246000
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4375000
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
548000 shares
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5118000
CY2016Q4 us-gaap Costs And Expenses
CostsAndExpenses
16449000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-10563000
CY2016Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10563000
CY2016Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
5627000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10822000
CY2016Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
259000
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11331000
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34507000 shares

Files In Submission

Name View Source Status
0001193125-17-082186-index-headers.html Edgar Link pending
0001193125-17-082186-index.html Edgar Link pending
0001193125-17-082186.txt Edgar Link pending
0001193125-17-082186-xbrl.zip Edgar Link pending
d284545d10k.htm Edgar Link pending
d284545dex211.htm Edgar Link pending
d284545dex231.htm Edgar Link pending
d284545dex311.htm Edgar Link pending
d284545dex312.htm Edgar Link pending
d284545dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g284545g13s82.jpg Edgar Link pending
g284545g57e16.jpg Edgar Link pending
g284545g74h42.jpg Edgar Link pending
g284545g79q95.jpg Edgar Link pending
ntla-20161231.xml Edgar Link completed
ntla-20161231.xsd Edgar Link pending
ntla-20161231_cal.xml Edgar Link unprocessable
ntla-20161231_def.xml Edgar Link unprocessable
ntla-20161231_lab.xml Edgar Link unprocessable
ntla-20161231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending